- Investing Ideas
- /
- U.S. Biotech Stocks
U.S. Biotech Stocks
Results
437
Even though biotechnology stocks can be very risky, they can also offer some of the biggest rewards with huge profits on offer when you find the right one. The companies below all have reasonable balance sheets and value, giving the best chance of finding a gem.
437 companies
Emergent BioSolutions
Market Cap: US$442.3m
A life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States.
EBS
US$8.74
7D
10.1%
1Y
20.1%
Cytek Biosciences
Market Cap: US$433.8m
A cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications.
CTKB
US$3.39
7D
-17.1%
1Y
-34.8%
Autolus Therapeutics
Market Cap: US$415.2m
A clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally.
AUTL
US$1.50
7D
10.3%
1Y
-56.9%
I-Mab
Market Cap: US$409.8m
A biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States.
IMAB
US$3.52
7D
-3.6%
1Y
217.1%
Assembly Biosciences
Market Cap: US$399.3m
A biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
ASMB
US$25.53
7D
14.6%
1Y
64.2%
CytomX Therapeutics
Market Cap: US$397.4m
Operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment.
CTMX
US$2.84
7D
39.2%
1Y
136.7%
4D Molecular Therapeutics
Market Cap: US$394.2m
A late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
FDMT
US$8.42
7D
18.6%
1Y
-23.2%
Aura Biosciences
Market Cap: US$383.3m
A clinical-stage biotechnology company, develops precision therapies to treat solid tumors.
AURA
US$5.88
7D
-6.1%
1Y
-34.7%
Pacific Biosciences of California
Market Cap: US$375.5m
Designs, develops, and manufactures sequencing solution to resolve genetically complex problems.
PACB
US$1.22
7D
-4.7%
1Y
-29.9%
Absci
Market Cap: US$372.3m
Operates as a data-first generative artificial intelligence (AI) drug creation company in the United States.
ABSI
US$2.65
7D
-1.5%
1Y
-35.5%
Benitec Biopharma
Market Cap: US$369.9m
A clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
BNTC
US$13.80
7D
-1.4%
1Y
57.0%
Design Therapeutics
Market Cap: US$366.7m
A clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
DSGN
US$6.11
7D
-2.2%
1Y
12.7%
Mesa Laboratories
Market Cap: US$365.4m
Develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.
MLAB
US$64.14
7D
-7.3%
1Y
-49.8%
Rocket Pharmaceuticals
Market Cap: US$358.2m
Operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States.
RCKT
US$3.19
7D
0.6%
1Y
-81.9%
enGene Holdings
Market Cap: US$357.3m
Through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer.
ENGN
US$6.50
7D
-6.6%
1Y
18.2%
Cullinan Therapeutics
Market Cap: US$356.2m
A clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States.
CGEM
US$5.99
7D
-5.5%
1Y
-65.4%
DiaMedica Therapeutics
Market Cap: US$354.1m
A clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases.
DMAC
US$6.84
7D
1.2%
1Y
59.1%
Altimmune
Market Cap: US$346.0m
A clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.
ALT
US$3.92
7D
1.3%
1Y
-42.4%
Quantum-Si
Market Cap: US$326.0m
A life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS).
QSI
US$1.51
7D
-1.3%
1Y
67.0%
Replimune Group
Market Cap: US$324.7m
A clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer.
REPL
US$4.05
7D
17.1%
1Y
-63.6%
Alector
Market Cap: US$319.8m
A late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases.
ALEC
US$2.93
7D
-6.4%
1Y
-39.1%
Amarin
Market Cap: US$319.3m
A pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally.
AMRN
US$15.45
7D
3.6%
1Y
32.4%
Annexon
Market Cap: US$309.9m
A clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.
ANNX
US$2.79
7D
5.7%
1Y
-54.4%
Alpha Teknova
Market Cap: US$303.4m
Produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
TKNO
US$5.79
7D
24.8%
1Y
28.4%
Candel Therapeutics
Market Cap: US$298.1m
A clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients.
CADL
US$5.27
7D
6.7%
1Y
-24.8%
Neumora Therapeutics
Market Cap: US$296.4m
A clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States.
NMRA
US$1.70
7D
8.3%
1Y
-87.0%
Contineum Therapeutics
Market Cap: US$294.4m
A clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States.
CTNM
US$10.86
7D
-12.4%
1Y
-41.8%
Vanda Pharmaceuticals
Market Cap: US$289.5m
A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
VNDA
US$4.83
7D
6.9%
1Y
1.9%
Omeros
Market Cap: US$285.8m
A clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.
OMER
US$4.38
7D
2.8%
1Y
11.7%
Abeona Therapeutics
Market Cap: US$284.6m
A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
ABEO
US$5.36
7D
-5.0%
1Y
-9.6%
Capricor Therapeutics
Market Cap: US$283.0m
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$6.52
7D
1.9%
1Y
-34.7%
Tectonic Therapeutic
Market Cap: US$280.5m
A biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs).
TECX
US$14.71
7D
-5.9%
1Y
-48.5%
Kyverna Therapeutics
Market Cap: US$278.5m
Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.
KYTX
US$6.35
7D
26.7%
1Y
21.0%
Allogene Therapeutics
Market Cap: US$272.9m
A clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
ALLO
US$1.20
7D
-0.8%
1Y
-55.9%
AC Immune
Market Cap: US$270.1m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$2.91
7D
15.5%
1Y
-21.4%
Forte Biosciences
Market Cap: US$267.5m
Operates as a clinical-stage biopharmaceutical company in the United States.
FBRX
US$14.25
7D
7.9%
1Y
144.8%